ERBB2 and neoplasm: This in turn induces resistance to trastuzumab and lapatinib, a reaction related to the mechanism by which FGFR2 inhibitors suppress tumor progression in trastuzumab-resistant and lapatinib-resistant cells and restore sensitivity to HER2-targeted therapies (44).